ATE150648T1 - Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) - Google Patents

Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)

Info

Publication number
ATE150648T1
ATE150648T1 AT92900612T AT92900612T ATE150648T1 AT E150648 T1 ATE150648 T1 AT E150648T1 AT 92900612 T AT92900612 T AT 92900612T AT 92900612 T AT92900612 T AT 92900612T AT E150648 T1 ATE150648 T1 AT E150648T1
Authority
AT
Austria
Prior art keywords
osteoporosis
grf
pth
releasing factor
conjunction
Prior art date
Application number
AT92900612T
Other languages
English (en)
Inventor
Robert R Recker
Original Assignee
Robert R Recker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert R Recker filed Critical Robert R Recker
Application granted granted Critical
Publication of ATE150648T1 publication Critical patent/ATE150648T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92900612T 1990-11-26 1991-11-01 Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) ATE150648T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61754390A 1990-11-26 1990-11-26
PCT/US1991/008106 WO1992009304A1 (en) 1990-11-26 1991-11-01 Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)

Publications (1)

Publication Number Publication Date
ATE150648T1 true ATE150648T1 (de) 1997-04-15

Family

ID=24474060

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900612T ATE150648T1 (de) 1990-11-26 1991-11-01 Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)

Country Status (13)

Country Link
US (1) US5164368A (de)
EP (1) EP0559751B1 (de)
JP (1) JP2557779B2 (de)
AT (1) ATE150648T1 (de)
AU (1) AU645874B2 (de)
CA (1) CA2096350C (de)
DE (1) DE69125394T2 (de)
DK (1) DK0559751T3 (de)
ES (1) ES2099245T3 (de)
FI (1) FI106776B (de)
IE (1) IE913858A1 (de)
NZ (1) NZ240482A (de)
WO (1) WO1992009304A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6074840A (en) * 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5700775A (en) * 1995-03-24 1997-12-23 Gutniak; Mark K. Method and treatment composition for decreasing patient time in catabolic state after traumatic injury
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
BR9709499A (pt) * 1996-05-31 1999-08-10 Novo Nordisk As Processo para prevenção ou tratamento de osteoporose e de perturbações relacionamas uso de um componente de hormónio do crescimento uso de uma composição com uma ação de anti-reabsorção sobre os ossos e produtos
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU2002300896B2 (en) * 1997-06-19 2006-03-30 Nps Pharmaceuticals, Inc. Method of enhancing bone mineral density
EP1007673B1 (de) 1997-07-30 2008-12-17 Emory University Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1119251A4 (de) * 1998-10-07 2004-03-24 Univ Arkansas Verfahren für das screening auf wirkstoffe für die anabole knochentherapie, die die apoptosis kontrollieren, und ihre verwendung
WO2000028982A2 (en) 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
ME02800B (de) 2009-12-01 2018-01-20 Abbvie Inc Neue trizyklische verbindungen
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870094A (en) * 1984-05-02 1989-09-26 Uniroyal Chemical Company, Inc. Substituted imidazoles and triazoles
US4710382A (en) 1985-09-27 1987-12-01 Recker Robert R Treatment for osteoporosis using hGRF(1-40)NH2
US4870054A (en) 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4833123A (en) * 1987-10-08 1989-05-23 Sumitomo Chemical Company Limited Yellow dye-donor element used in thermal transfer and thermal transfer and thermal transfer sheet using it
EP0326418A1 (de) * 1988-01-29 1989-08-02 The Upjohn Company GRF-Analoge

Also Published As

Publication number Publication date
DE69125394T2 (de) 1997-08-21
DK0559751T3 (da) 1997-10-06
JPH06502863A (ja) 1994-03-31
DE69125394D1 (de) 1997-04-30
AU9073591A (en) 1992-06-25
US5164368A (en) 1992-11-17
FI932385A0 (fi) 1993-05-26
IE913858A1 (en) 1992-06-03
WO1992009304A1 (en) 1992-06-11
ES2099245T3 (es) 1997-05-16
FI932385L (fi) 1993-05-26
EP0559751B1 (de) 1997-03-26
CA2096350A1 (en) 1992-05-27
NZ240482A (en) 1997-06-24
EP0559751A1 (de) 1993-09-15
JP2557779B2 (ja) 1996-11-27
CA2096350C (en) 2001-10-16
AU645874B2 (en) 1994-01-27
FI106776B (fi) 2001-04-12
EP0559751A4 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
ATE150648T1 (de) Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
RU95110107A (ru) Способ получения стабильного кристаллического аналога цинк-инсулина
BR8603315A (pt) Processo para produzir um implante de liberacao controlada;implante usado no processo;processo para purificar e concentrar hormonio de crescimento biologicamente ativo em uma forma adequada para incorporacao em um implante para administracao subcutanea
CA2124792A1 (en) Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone
FI950169L (fi) PTH:n ja PTHRP:n analogit, niiden synteesi ja käyttö osteoporoosin hoitoon
DE3866817D1 (de) Knochenzement zur kontrollierten abgabe von wirkstoffen.
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
YU46794A (sh) Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena
FI952701A0 (fi) Metallisen kirurgisen istukkaan käsittelymenetelmä
DE69008476D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose.
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
CA2032123A1 (fr) Dispositif de renfort et de soutien de la coiffe des rotateurs d'une articulation d'epaule d'individus
GB9316895D0 (en) Hepatoselective insulin analogues
SE8405596D0 (sv) A method of producing a mono- or multilayered prothesis material and the material hereby obtained
ES2101833T3 (es) Utilizacion de igf-i humano.
CA2101275A1 (en) Methods for the treatment of osteoporosis
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
GEP20033095B (en) Parathyroid Hormone Analogues for the Treatment of Osteoporosis
FR2655276B1 (fr) Microemulsions concentrees de matieres organiques diluables sous forme d'emulsions stables et leur procede de preparation.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
CA2074166A1 (en) Method for treating intestinal diseases
ATE141789T1 (de) Zusammensetzung enthaltend dibucaine- hydrochlorid, ein salicylat, calciumbromid und ein antiphlogistisches steroid zur schmerzbekämpfung
ROGACHEVA Effects of calcitonin and retabolil on rat femur in hypokinesia(Abstract Only)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee